"ErbB Receptors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of structurally-related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS.
| Descriptor ID |
D066246
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009 D12.776.543.750.630.009 D12.776.543.750.750.400.074
|
| Concept/Terms |
ErbB Receptors- ErbB Receptors
- Receptors, ErbB
- Receptors, Epidermal Growth Factor-Urogastrone
- Receptors, Epidermal Growth Factor Urogastrone
- Receptors, Epidermal Growth Factor
- EGF Receptors
- Receptors, EGF
- Epidermal Growth Factor Receptor Family Proteins
- HER Family Receptors
- Family Receptors, HER
- Receptors, HER Family
- Erb-b2 Receptor Tyrosine Kinases
- Erb b2 Receptor Tyrosine Kinases
|
Below are MeSH descriptors whose meaning is more general than "ErbB Receptors".
Below are MeSH descriptors whose meaning is more specific than "ErbB Receptors".
This graph shows the total number of publications written about "ErbB Receptors" by people in this website by year, and whether "ErbB Receptors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 11 | 6 | 17 |
| 1995 | 10 | 1 | 11 |
| 1996 | 14 | 6 | 20 |
| 1997 | 13 | 3 | 16 |
| 1998 | 12 | 5 | 17 |
| 1999 | 7 | 8 | 15 |
| 2000 | 16 | 7 | 23 |
| 2001 | 16 | 5 | 21 |
| 2002 | 19 | 12 | 31 |
| 2003 | 26 | 8 | 34 |
| 2004 | 34 | 14 | 48 |
| 2005 | 23 | 22 | 45 |
| 2006 | 33 | 24 | 57 |
| 2007 | 49 | 28 | 77 |
| 2008 | 36 | 26 | 62 |
| 2009 | 26 | 42 | 68 |
| 2010 | 40 | 34 | 74 |
| 2011 | 34 | 33 | 67 |
| 2012 | 29 | 25 | 54 |
| 2013 | 35 | 13 | 48 |
| 2014 | 19 | 15 | 34 |
| 2015 | 31 | 22 | 53 |
| 2016 | 22 | 23 | 45 |
| 2017 | 13 | 18 | 31 |
| 2018 | 2 | 31 | 33 |
| 2019 | 3 | 27 | 30 |
| 2020 | 3 | 37 | 40 |
| 2021 | 4 | 17 | 21 |
| 2022 | 1 | 30 | 31 |
| 2023 | 0 | 20 | 20 |
| 2024 | 7 | 4 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "ErbB Receptors" by people in Profiles.
-
Synergistic activation by Glass and Pointed promotes neuronal identity in the Drosophila eye disc. Nat Commun. 2024 Aug 17; 15(1):7091.
-
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Clin Cancer Res. 2024 Aug 01; 30(15):3287-3297.
-
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance. Nat Cancer. 2024 Aug; 5(8):1250-1266.
-
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024 Aug 15; 391(7):585-597.
-
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun. 2024 May 03; 15(1):3741.
-
Changing Fate: How EGFRs "Pit" Cell Versus Cell in the Stomach. Gastroenterology. 2024 Aug; 167(3):441-442.
-
Antibody-Conjugated Polymersomes with Encapsulated Indocyanine Green J-Aggregates and High Near-Infrared Absorption for Molecular Photoacoustic Cancer Imaging. ACS Appl Mater Interfaces. 2024 Feb 07; 16(5):5598-5612.
-
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun; 19(6):928-940.
-
Integrative genomic analyses reveal putative cell type-specific targets of the Drosophila ets transcription factor Pointed. BMC Genomics. 2024 Jan 23; 25(1):103.
-
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30(1):265-270.